Friday, April 1, 2022

EU OK for AZ’s Calquence in CLL

The European Commission has approved AstraZeneca’s Calquence (acalabrutinib)for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).

Calquence, a selective Bruton’s tyrosine kinase (BTK) inhibitor, was approved based on results from two phase III clinical trials – ELEVATE-TN in patients with previously untreated CLL and ASCEND in patients with relapsed or refractory CLL.

In the ELEVATE-TN trial, Calquence combined with Obinutuzumab and as a monotherapy reduced the risk of disease progression or death by 90% and 80% respectively in patients with previously untreated CLL.

Added to those results was the positive data from the ASCEND trial, which demonstrated that 88% of patients with relapsed or refractory CLL receiving Calquence remained alive and free from disease progression after 12 months, compared with 68% of patients on Roche’s Rituxan (rituximab) combined with idelalisib or bendamustine.

“This approval represents a key development for patients in Europe who until now have had limited chemotherapy-free treatment options,” said Dave Fredrickson, executive vice president, oncology business unit, AZ.

“As our first European approval in blood cancers, Calquence provides a new tolerable treatment option with uncompromised efficacy and the potential to positively impact the quality of life for thousands of patients living with chronic lymphocytic leukaemia,” he added.

CLL is the most common type of leukaemia in adults, with approximately 105,000 new cases diagnosed globally in 2016.

This type of blood cancer is characterised by too many blood stem cells in bone marrow becoming abnormal lymphocytes – these abnormal cells have difficulty fighting off infections.

Calquence is already approved in the US for the treatment of CLL as well as small lymphocytic lymphoma and is approved for CLL in several other countries worldwide.

The BTK inhibitor is also approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy in the US and a number of other countries.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...